MRK vs NVS vs SNY Stock Comparison

Merck, Novartis Ag and Sanofi Prices as of Nov 13, 2026 Peers: Industry group
MRK Merck & Co., Inc.
$147.78 +0.3% 1M +59.0% 1Y
Market cap
$361.12B
P/E
147.2x
Revenue (TTM)
$67.38B
Div. yield
0.02%
Pharmaceuticals Healthcare
3 wins
NVS Novartis Ag
$160.55 +9.3% 1M +21.7% 1Y
Market cap
$312.86B
P/E
17.9x
Revenue (TTM)
—
Div. yield
–
Pharmaceuticals Healthcare
1 win
SNY Sanofi
$48.37 +21.6% 1M -7.6% 1Y
Market cap
$59.20B
P/E
6.3x
Revenue (TTM)
$55.00B
Div. yield
–
Pharmaceuticals Healthcare
5 wins

Head to Head

9 decided of 12

Sanofi leads on 5 of the 12 questions below (Sanofi 5, Merck 3, Novartis Ag 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMRKNVSSNYLeader
Larger companyMarket capitalisation $361.12B $312.86B $59.20B MRK
Cheaper on earningsLower P/E, profitable companies only 147.2x 17.9x 6.3x SNY
Cheaper on forward earningsLower price / next fiscal year consensus EPS 56.6x 17.1x 10.4x SNY
Faster revenue growthRevenue growth, trailing twelve months +4.9% — -19.6% MRK
More profitableNet margin, trailing twelve months 3.6% — 17.2% SNY
Better return on capitalReturn on invested capital 2.5% — — –
Less leveragedLower net debt / EBITDA 3.6x — — –
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +59.0% +21.7% -7.6% MRK
Better 5-year returnAnnualised price return, 5 years +12.0%/yr +14.3%/yr -1.0%/yr NVS
Less volatileAnnualised volatility, 1 year 29.6% 27.8% 24.1% SNY
Higher overall scoreMean of the five percentile scores vs peers 61/100 — 83/100 SNY

Percentile Scorecard

MRKNVSSNY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMRKNVSSNY
Valuation 85 #97 of 660 96 #26 of 660 99 #11 of 660
Growth 30 #434 of 619 – 55 #280 of 619
Profitability 90 #59 of 595 – 95 #30 of 595
Financial Health 21 #538 of 683 – –
Shareholder Returns 79 #98 of 459 79 #97 of 459 85 #68 of 459
Overall 61 – 83
  • MRK ranked among 695 companies in Pharmaceuticals and Biotechnology
  • NVS ranked among 695 companies in Pharmaceuticals and Biotechnology
  • SNY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMRKNVSSNYSPY
1 month +0.3%+9.3%+21.6% -2.0%
3 months +8.8%+6.4%+10.6% -2.8%
6 months +32.7%+8.4%+13.3% +2.0%
Year to date +40.4%+16.5%-0.2% +10.6%
1 year +59.0%+21.7%-7.6% +12.2%
3 years +44.6%+69.2%+5.8% +68.1%
3 years, per year +13.1%+19.2%+1.9% +18.9%
5 years +75.9%+94.6%-4.7% +61.4%
5 years, per year +12.0%+14.3%-1.0% +10.1%
10 years +131.1%+118.5%+17.9% +248.5%
10 years, per year +8.7%+8.1%+1.7% +13.3%

Risk

MeasureMRKNVSSNYSPY
Volatility, 1Y 29.6%27.8%24.1% 13.6%
Downside volatility, 1Y 24.1%30.0%24.8% 13.9%
Beta vs S&P 500, 1Y 0.200.360.28 1.00
Return / volatility, 1Y 1.990.78-0.31 0.90
Max drawdown, 5Y -44.7%-20.4%-35.2% -25.4%
From 52-week high -5.5%-4.8%-7.6% -3.2%
52-week high $156.45$168.62$52.34 $779.14
52-week low $92.86$124.36$39.12 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMRKNVSSNY
P/E now vs peer median 148.7xmedian 17.0x 17.9xmedian 17.0x 6.2xmedian 17.0x
P/S now vs peer median 5.4xmedian 8.4x 5.1xmedian 8.4x 1.1xmedian 8.4x
EV/EBITDA now vs peer median 33.7xmedian 14.6x —median 14.6x 8.5xmedian 14.6x
P/FCF now vs peer median 24.7xmedian 19.0x 14.3xmedian 19.0x 4.1xmedian 19.0x
P/B now vs peer median 8.1xmedian 2.0x —median 2.0x —median 2.0x
PEG now vs peer median -8.16median 0.43 —median 0.43 24.27median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMRKNVSSNY
Revenue $67.38B – $55.00B
Gross profit $48.35B – $63.47B
Operating income $4.76B – $11.14B
Net income $2.45B – $7.19B
Free cash flow $14.75B – $14.54B
R&D $30.76B – $17.81B
EPS (diluted) $0.99 – $7.72
Cash & equivalents $9.55B $400.00M $6.77B
Total debt $53.78B – –
Shares (diluted) 2.48B 1.96B 1.23B
Enterprise value $324.06B $286.10B $29.40B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMRKNVSSNY
P/E 148.7x 17.9x 6.2x
P/FCF 24.7x 14.3x 4.1x
P/Operating cash flow 19.5x – 3.2x
P/S 5.4x 5.1x 1.1x
P/B 8.1x – –
P/Tangible book 17.8x – –
EV/EBITDA 33.7x – 8.5x
EV/EBIT 85.8x – 4.7x
EV/Revenue 6.1x – 0.9x
EV/FCF 27.7x – 3.6x
EV/Operating cash flow 21.8x – 2.8x
PEG (3Y EPS CAGR) -8.16 – 24.27

Growth

14 metrics
MetricMRKNVSSNY
Revenue growth (1Y) 4.9% – -19.6%
Revenue CAGR (3Y) 4.3% – 6.3%
Gross profit growth (1Y) -2.5% – 86.6%
Gross profit CAGR (3Y) 3.8% – 23.2%
Operating income growth (1Y) -78.2% – 24.9%
Operating income CAGR (3Y) -13.9% – -3.4%
Net income growth (1Y) -87.1% – -30.1%
Net income CAGR (3Y) -19.1% – -9.6%
EPS growth (1Y) -87.0% – -12.4%
EPS CAGR (3Y) -18.2% – 0.3%
Operating cash flow growth (1Y) 9.6% – 45.1%
Operating cash flow CAGR (3Y) 2.9% – 20.9%
Free cash flow growth (1Y) 13.0% – -10.0%
Free cash flow CAGR (3Y) 3.8% – 11.9%

Profitability

14 metrics
MetricMRKNVSSNY
Gross margin 71.8% – 115.4%
EBITDA margin 18.0% – 11.2%
Operating margin 7.1% – 20.3%
Pretax margin 7.1% – 22.9%
Net margin 3.6% – 17.2%
FCF margin 21.9% – 26.4%
Operating cash flow margin 27.8% – 33.5%
Return on equity 5.6% – –
Return on assets 1.9% – 4.9%
Return on invested capital 2.5% – –
Return on capital employed 4.6% – –
Asset turnover 0.5x – 0.4x
Cash conversion (OCF / net income) 7.6x – 2.6x
Stock comp / revenue 1.6% – –

Financial Health

11 metrics
MetricMRKNVSSNY
Debt / assets 40.5% – –
Debt / equity 1.2x – –
Net debt / EBITDA 3.6x – –
Debt / FCF 3.6x – –
Liabilities / assets 66.1% – –
Equity / assets 33.9% – –
Interest coverage – – 11.9x
Current ratio 1.4x – –
Quick ratio 0.8x – –
Cash ratio 0.3x – –
Altman Z-score 3.90 – –

Shareholder Returns

7 metrics
MetricMRKNVSSNY
Dividend yield 2.3% 3.0% 5.0%
Net buyback yield 0.8% – -0.2%
Shareholder yield 3.1% 3.0% 4.8%
Payout ratio (earnings) 341.6% – –
Payout ratio (FCF) 56.7% – –
Dividend growth (1Y) 3.2% – –
Dividend CAGR (3Y) 4.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMRKNVSSNY
Forward P/E 56.6xFY2026 17.1xFY2026 10.4xFY2026
EPS, next fiscal year $2.61FY2026 $9.38FY2026 $4.67FY2026
EPS growth, next FY -70.9%FY2026 +4.5%FY2026 0.0%FY2026
EPS growth, the year after +228.7% +0.9% +5.8%
Revenue, next fiscal year $69.66BFY2026 $53.97BFY2026 $54.79BFY2026
Revenue growth, next FY +7.2%FY2026 -1.0%FY2026 -0.5%FY2026
Revenue growth, the year after -4.6% +19.3% +14.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMRKNVSSNY
Held by institutions 79.9% 7.0% 15.5%
Institutions holding 3,804 1,610 719
Change in shares held, QoQ +2.6% -6.0% -9.8%
Institutions buying 1,844 662 304
Institutions selling 1,469 562 294
Buyers to sellers 1.26 1.18 1.03

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MRKNVSSNY
MRK 1.00 0.48 0.38
NVS 0.48 1.00 0.46
SNY 0.38 0.46 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MRK, NVS and SNY?

Merck (MRK) is the largest by market capitalisation: Merck (MRK) $361.12B, Novartis Ag (NVS) $312.86B, Sanofi (SNY) $59.20B.

Which stock is cheaper, MRK, NVS and SNY?

Sanofi (SNY) trades on the lowest price-to-earnings ratio (Merck (MRK) 147.2x, Novartis Ag (NVS) 17.9x, Sanofi (SNY) 6.3x). On next year's consensus earnings, Sanofi (SNY) is cheapest (Merck (MRK) 56.6x, Novartis Ag (NVS) 17.1x, Sanofi (SNY) 10.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Merck (MRK) grew revenue fastest over the trailing twelve months: Merck (MRK) +4.9%, Sanofi (SNY) -19.6%.

Which company is more profitable?

Sanofi (SNY) has the highest net margin (Merck (MRK) 3.6%, Sanofi (SNY) 17.2%).

Which stock has performed better?

Over the past year Merck (MRK) returned the most: Merck (MRK) +59.0%, Novartis Ag (NVS) +21.7%, Sanofi (SNY) -7.6%. Over five years, Novartis Ag (NVS) compounded fastest (Merck (MRK) +12.0%/yr, Novartis Ag (NVS) +14.3%/yr, Sanofi (SNY) -1.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Merck (MRK) 0.02%, Novartis Ag (NVS) 0.00%, Sanofi (SNY) 0.00%. Novartis Ag (NVS) and Sanofi (SNY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Sanofi (SNY) has been the steadiest (Merck (MRK) 29.6%, Novartis Ag (NVS) 27.8%, Sanofi (SNY) 24.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, MRK, NVS and SNY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Sanofi (SNY) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.